# Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Source: https://onco.cc/trials/nct03944772/  
OnCo record `nct03944772` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Osimertinib, Savolitinib, Gefitinib in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) is a phase 2 interventional study registered as NCT03944772 by AstraZeneca, with 247 participants enrolled, started 2019-06-25 and due to reach its primary completion in 2025-05-06. Interventions recorded: Osimertinib, Savolitinib, Gefitinib, Necitumumab, Durvalumab. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03944772
- Phase: 2
- Setting: A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy.
- Sponsor: AstraZeneca
- Enrolled: 247

## Sources

- ClinicalTrials.gov NCT03944772: https://clinicaltrials.gov/study/NCT03944772

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Gefitinib](https://onco.cc/drugs/gefitinib/), [Necitumumab](https://onco.cc/drugs/necitumumab/), [Osimertinib](https://onco.cc/drugs/osimertinib/), [Savolitinib](https://onco.cc/drugs/savolitinib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct03944772.json